Inmode Ltd. Stock Price, News & Analysis

On January 12, 2021, InMode Ltd. (Nasdaq: INMD) announced its expectation for record revenues in Q4 2020, projected between $74.5 million to $75 million, and a full-year total of $205.5 million to $206 million. This surpasses prior guidance of $192 million to $195 million. Non-GAAP earnings per diluted share are expected to be $0.91 to $0.93 for Q4 and $2.08 to $2.10 for the full year. Additionally, the company provided a revenue guidance of $250 million to $260 million for 2021.

InMode Ltd. (Nasdaq: INMD) announced its participation in the 2021 ICR Conference held virtually from January 11-14, 2021. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will engage in a fireside chat on January 14, 2021, at 3:15 pm EST. A live webcast will be accessible to the public and archived for 90 days post-event. InMode specializes in innovative medical technologies utilizing radio-frequency (RF) technology, enhancing surgical procedures across multiple medical fields.

InMode Ltd. (Nasdaq: INMD) is set to present its corporate social responsibility (CSR) strategy in its annual 20-F filing, highlighting sustainable practices as it expands into new markets. The strategy aims to enhance local economies and stakeholder engagement. The first CSR report will focus on Product Safety and Supply Chain Management, aligning with sustainability metrics outlined by the SASB. CEO Moshe Mizrahy emphasized the company's commitment to safe, non-invasive medical devices that improve patient quality of life.

InMode Ltd. (Nasdaq: INMD) announced that CEO Moshe Mizrahy and CFO Yair Malca will present at the 23rd Annual Needham Growth Conference on January 14, 2021, at 8:30 am EST. The presentation will be available via live webcast to the public at their investor relations website, with an archive accessible for 90 days post-event. InMode specializes in innovative medical technologies utilizing radio-frequency technology, focusing on enhancing surgical and treatment processes across various medical fields.

La Belle Vie MedSpa & Wellness Center announces the grand opening of the Oasis Treatment Tent, a COVID-friendly outdoor setup featuring InMode's non-invasive Evolve and Forma treatments. Evolve is a hands-free platform designed for skin remodeling and muscle toning, reducing in-person interactions. Forma utilizes bipolar radiofrequency to enhance skin texture and is safe for all skin types. The tent opens on November 28, providing an innovative aesthetic solution while prioritizing health and safety.

InMode Ltd. (Nasdaq: INMD) reported record Q3 2020 revenues of $59.7 million, a 49% increase year-over-year. The company achieved a GAAP net income of $23.9 million, up from $16.2 million in Q3 2019, resulting in a diluted EPS of $0.57. Key revenue drivers included its proprietary surgical technology platforms and new hands-free solutions. Cash position stands at $234.3 million. Management anticipates 2020 revenues to be between $192 million and $195 million, with expected non-GAAP gross margins of 84%-86%.

Nanowear has received FDA Class II 510(k) clearance for SimpleSENSE, a groundbreaking cloth-based diagnostic platform. This multi-parameter remote diagnostic undergarment synchronously monitors cardiac, pulmonary, and circulatory health, capturing over 100 million data points daily. With the demand for telemedicine rising, SimpleSENSE offers clinicians a powerful tool for early patient intervention. As a response to the COVID-19 pandemic, Nanowear aims to assist in remote diagnostics across various healthcare areas. The company also plans to continue clinical trials related to heart failure and COVID-19.

InMode Ltd. (Nasdaq: INMD) announced the US Patent and Trademark Office has granted Patent No. 10.799.285 for its Morpheus8 full body fractional radiofrequency technology. This patent is part of InMode's strategy to protect its intellectual property and enhance shareholder value. The company has actively issued cease and desist notices to North American companies infringing on this patent. InMode's ongoing R&D efforts have established it as a leader in the medical aesthetics field, particularly with its Morpheus8 Subdermal Adipose Remodeling device.

InMode Ltd. (Nasdaq: INMD) announced a peer-reviewed study published in Lasers in Surgery and Medicine exploring the risks associated with plume emissions during skin resurfacing procedures. Conducted by leading medical professionals, the study found that the Erbium: YAG laser emitted over four times more particles than InMode's Morpheus8 fractional RF device, which showed minimal plume emission. The findings support the safety of Morpheus8 technology in elective procedures, according to InMode executives.